Xylem said revenue for Q1 2025 rose to $2.1 billion, up 2% on a reported basis and 3% on an organic basis. The company said strong execution and demand were partly offset by foreign exchange headwinds.

1. 01

   Xylem said revenue for Q1 2025 rose to $2.1 billion, up 2% on a reported basis and 3% on an organic basis. The company said strong execution and demand were partly offset by foreign exchange headwinds.

2. 02

   The company said net income attributable to Xylem for Q1 was $169 million, or $0.69 per share. Adjusted net income was $251 million, or $1.03 per share, excluding purchase accounting intangible amortization and other items.

3. 03

   Xylem said its adjusted EBITDA margin for Q1 was 20.4%, up 120 basis points from a year earlier. The company attributed the margin expansion to productivity savings and strong price realization, which exceeded the impact of inflation and mix.

4. 04

   Xylem expects full-year revenue of approximately $8.7 to $8.8 billion, up approximately 1 to 2% on a reported basis, compared with the prior guidance of 0 to 2%, the company said. Full-year adjusted earnings per share is expected to be $4.50 to $4.70, in line with the previous guidance range.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.